← Leaderboards
Antonio Bedalov
Fred Hutchinson Cancer Research Center
$9,672,543
Attributed
$12,328,220
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,328,220 · 6
By mechanism
R01$11,381,094 · 4
K08$506,520 · 1
R21$440,606 · 1
Top collaborators
- Julian A Simon6 shared
- X. Shawn Liu3 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Julian A Simon$13,150,957
- Manish Sagar$13,597,051
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsProteinsChromatinMutationGenesEnzymesGenetic TranscriptionBaseMalignant NeoplasmsProgramsPathway InteractionsLeadGeneticIn VitroMouse ModelIn VivoTransgenic MiceYeastsRepressionMediatingS LymphomaSpecificityCarcinogenesisAnalog
Grant awards (30)
MeCP2 reactivation from the inactive X chromosome as treatment for Rett syndrome$797,991
R01 · FY2025 · MH
MeCP2 reactivation from the inactive X chromosome as treatment for Rett syndrome$809,324
R01 · FY2024 · MH
MeCP2 reactivation from the inactive X chromosome as treatment for Rett syndrome$848,974
R01 · FY2023 · MH
Origin firing at repetitive sequences and genome replication$553,339
R01 · FY2023 · GM · contact PI
Origin firing at repetitive sequences and genome replication$553,339
R01 · FY2022 · GM · contact PI
Origin firing at repetitive sequences and genome replication - Admin Supplement$7,960
R01 · FY2022 · GM · contact PI
Origin firing at repetitive sequences and genome replication$553,339
R01 · FY2021 · GM · contact PI
Origin firing at repetitive sequences and genome replication$553,339
R01 · FY2020 · GM · contact PI
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$467,882
R01 · FY2020 · CA
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$106,872
R01 · FY2020 · CA
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$557,510
R01 · FY2019 · CA
Origin firing at repetitive sequences and genome replication$454,813
R01 · FY2019 · GM · contact PI
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$574,754
R01 · FY2018 · CA
Origin firing at repetitive sequences and genome replication$568,439
R01 · FY2018 · GM · contact PI
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$574,754
R01 · FY2017 · CA
Origin firing at repetitive sequences and genome replication$454,813
R01 · FY2017 · GM · contact PI
Administrative Supplement to Parent Grant R01 GM117446, Origin Firing at Repetitive Sequences and Genome Replication, FOA Title: Research Supplements to Promote Diversity in Health-Related Research$93,954
R01 · FY2017 · GM · contact PI
SIRT2 Inhibitors for the Treatment of B-cell Lymphoma$573,293
R01 · FY2016 · CA
Origin firing at repetitive sequences and genome replication$472,317
R01 · FY2016 · GM · contact PI
Protein Biomarkers in Childhood Acute Myeloid Leukemia$194,919
R21 · FY2013 · CA · contact PI
Development of cambinol analogues as antilymphoma agents$354,244
R01 · FY2012 · CA · contact PI
Protein Biomarkers in Childhood Acute Myeloid Leukemia$245,687
R21 · FY2012 · CA · contact PI
Development of cambinol analogues as antilymphoma agents$354,244
R01 · FY2011 · CA · contact PI
Development of cambinol analogues as antilymphoma agents$365,200
R01 · FY2010 · CA · contact PI
Development of cambinol analogues as antilymphoma agents$365,200
R01 · FY2009 · CA · contact PI
Development of cambinol analogues as antilymphoma agents$365,200
R01 · FY2008 · CA · contact PI
REGULATION OF TELOMERE LENGTH IN S CEREVISIAE$126,630
K08 · FY2003 · HL
REGULATION OF TELOMERE LENGTH IN S CEREVISIAE$126,630
K08 · FY2002 · HL
REGULATION OF TELOMERE LENGTH IN S CEREVISIAE$126,630
K08 · FY2001 · HL
REGULATION OF TELOMERE LENGTH IN S CEREVISIAE$126,630
K08 · FY2000 · HL